Abstract | BACKGROUND: METHODS: RESULTS: Although no patients had an objective response, 4 of 12 patients with secretory myeloma exhibited evidence of M- protein stabilization, and several other patients experienced improvement in bone pain and resolution of hypercalcemia. CONCLUSIONS: The results of the current study demonstrate that romidepsin, as a single agent, is unlikely to be associated with a response rate of ≥30% in patients with refractory myeloma, although there was some clinical evidence suggesting a biological effect associated with therapy.
|
Authors | Ruben Niesvizky, Scott Ely, Tomer Mark, Sangeeta Aggarwal, Janice L Gabrilove, John J Wright, Selina Chen-Kiang, Joseph A Sparano |
Journal | Cancer
(Cancer)
Vol. 117
Issue 2
Pg. 336-42
(Jan 15 2011)
ISSN: 0008-543X [Print] United States |
PMID | 20862746
(Publication Type: Clinical Trial, Phase II, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2010 American Cancer Society. |
Chemical References |
- Depsipeptides
- Histone Deacetylase Inhibitors
- Myeloma Proteins
- multiple myeloma M-proteins
- romidepsin
|
Topics |
- Aged
- Bone and Bones
(drug effects)
- Depsipeptides
(adverse effects, therapeutic use)
- Drug Administration Schedule
- Female
- Histone Deacetylase Inhibitors
(therapeutic use)
- Humans
- Male
- Middle Aged
- Multiple Myeloma
(drug therapy)
- Myeloma Proteins
(metabolism)
- Pain
(drug therapy)
- Retreatment
|